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ABSTRACT
OBJECTIVES
To examine the association between cognitively 
stimulating work and subsequent risk of dementia and 
to identify protein pathways for this association.
DESIGN
Multicohort study with three sets of analyses.
SETTING
United Kingdom, Europe, and the United States.
PARTICIPANTS
Three associations were examined: cognitive 
stimulation and dementia risk in 107 896 participants 
from seven population based prospective cohort 
studies from the IPD-Work consortium (individual 
participant data meta-analysis in working 
populations); cognitive stimulation and proteins in a 
random sample of 2261 participants from one cohort 
study; and proteins and dementia risk in 13 656 
participants from two cohort studies.
MAIN OUTCOME MEASURES
Cognitive stimulation was measured at baseline 
using standard questionnaire instruments on active 
versus passive jobs and at baseline and over time 
using a job exposure matrix indicator. 4953 proteins 
in plasma samples were scanned. Follow-up of 
incident dementia varied between 13.7 to 30.1 years 
depending on the cohort. People with dementia were 
identified through linked electronic health records 
and repeated clinical examinations.
RESULTS
During 1.8 million person years at risk, 1143 people 
with dementia were recorded. The risk of dementia was 
found to be lower for participants with high compared 
with low cognitive stimulation at work (crude incidence 
of dementia per 10 000 person years 4.8 in the high 
stimulation group and 7.3 in the low stimulation 
group, age and sex adjusted hazard ratio 0.77, 95% 
confidence interval 0.65 to 0.92, heterogeneity 
in cohort specific estimates I2=0%, P=0.99). This 
association was robust to additional adjustment for 
education, risk factors for dementia in adulthood 
(smoking, heavy alcohol consumption, physical 
inactivity, job strain, obesity, hypertension, and 
prevalent diabetes at baseline), and cardiometabolic 
diseases (diabetes, coronary heart disease, stroke) 
before dementia diagnosis (fully adjusted hazard ratio 
0.82, 95% confidence interval 0.68 to 0.98). The risk of 
dementia was also observed during the first 10 years of 
follow-up (hazard ratio 0.60, 95% confidence interval 
0.37 to 0.95) and from year 10 onwards (0.79, 0.66 
to 0.95) and replicated using a repeated job exposure 
matrix indicator of cognitive stimulation (hazard 
ratio per 1 standard deviation increase 0.77, 95% 
confidence interval 0.69 to 0.86). In analysis controlling 
for multiple testing, higher cognitive stimulation at 
work was associated with lower levels of proteins 
that inhibit central nervous system axonogenesis and 
synaptogenesis: slit homologue 2 (SLIT2, fully adjusted 
β −0.34, P<0.001), carbohydrate sulfotransferase 
12 (CHSTC, fully adjusted β −0.33, P<0.001), and 
peptidyl-glycine α-amidating monooxygenase (AMD, 
fully adjusted β −0.32, P<0.001). These proteins were 
associated with increased dementia risk, with the 
fully adjusted hazard ratio per 1 SD being 1.16 (95% 
confidence interval 1.05 to 1.28) for SLIT2, 1.13 (1.00 
to 1.27) for CHSTC, and 1.04 (0.97 to 1.13) for AMD.
CONCLUSIONS
The risk of dementia in old age was found to be lower 
in people with cognitively stimulating jobs than in 
those with non-stimulating jobs. The findings that 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Cognitive stimulation is assumed to prevent or postpone the onset of dementia, 
but trials, typically based on relatively small sample sizes and short term 
interventions, have reported inconsistent results, and most recent long term 
cohort studies have suggested that leisure time cognitive activity does not 
reduce risk of dementia
One reason for modest findings could be that the cognitive stimulation in these 
studies has not been intensive or engaging enough to preserve cognitive function
Exposure to cognitive stimulation at work lasts considerably longer than 
cognitive interventions, or, typically, cognitively stimulating hobbies; however, 
studies of cognitive stimulation at work to date have been small with insufficient 
control for confounding factors and have failed to produce compelling evidence 
of benefits
WHAT THIS STUDY ADDS
In this multicohort study of 107 896 participants, the risk of dementia in old age 
was found to be lower in individuals with cognitively stimulating jobs than in 
those with non-stimulating jobs
This finding was robust to adjustments for education, established dementia risk 
factors in adulthood, and the competing risk of death
Cognitive stimulation was also associated with lower levels of plasma proteins 
that might inhibit axonogenesis and synaptogenesis and increase dementia risk
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cognitive stimulation is associated with lower levels of 
plasma proteins that potentially inhibit axonogenesis 
and synaptogenesis and increase the risk of 
dementia might provide clues to underlying biological 
mechanisms.
Introduction
Cognitive stimulation has been hypothesised to 
help preserve cognitive function and decrease the 
risk of dementia in old age.1 Studies to date that 
have focused on cognitive stimulation in adulthood, 
however, have been small and with insufficient control 
for confounding factors and have failed to produce 
compelling evidence of benefits.2 3 Trials, typically 
based on relatively small sample sizes and short term 
interventions, have reported inconsistent results.4-6 
Most of the recent long term cohort studies have 
suggested that leisure time cognitive activity does not 
reduce the risk of dementia either.7-9 A progressive 
reduction occurs in cognitive activities before dementia 
onset, but this seems to be because the gradual onset 
of dementia results in inactivity rather than lower 
cognitive activity being related to dementia.7 8
It is unclear whether the reason for modest findings 
is that the decrease in brain plasticity with age 
prevents cognitive activities across adult life from 
conferring protection against dementia, or, in the case 
of interventions, that the cognitive stimulation studied 
has not been intensive or engaging enough to preserve 
cognitive function. Work roles might be useful in the 
study of these associations. Exposure to cognitive 
stimulation at work can extend over decades and 
amount to tens of thousands of hours, so this stimulation 
lasts considerably longer than cognitive interventions 
or, typically, cognitively stimulating hobbies. According 
to the demand-control model, cognitively stimulating 
“active” jobs include demanding tasks and high job 
decision latitude (also known as job control).10 11 
Non-stimulating “passive” jobs are those with low 
demands and lack of job control. The combination of 
high demands and low control, in turn, characterises 
stressful work or job strain, which might be a risk rather 
than a protective factor for dementia.12 13
In this report from the IPD-Work consortium 
(individual participant data meta-analysis in working 
populations),14 a large ongoing multicohort study of 
work and health, we examined the association between 
cognitively stimulating work and subsequent risk of 
dementia, controlling for established dementia risk 
factors and job strain. To identify potential biological 
pathways for this association, we performed a data 
driven analysis of 4953 plasma proteins, measured using 
slow off-rate modified aptamers.15 Plasma proteins are 
relevant targets for mechanistic study because they are 
affected by environmental exposures and serve many 
functions in regeneration, degeneration, and disease.15-17
Methods
Study populations
Established at the Four Centres meeting in London 
in 2008, the IPD-Work consortium is a collaborative 
research project of 13 European cohort studies, which 
aims to estimate associations between work related 
factors and chronic diseases, disability, and mortality. 
To meet this goal, the consortium uses predefined 
exposure definitions (to minimise selective reporting) 
and large pooled datasets (to allow confirmation of 
findings across subgroups and, in the case of null 
findings, to show and publish absence of associations 
convincingly).
Seven of the 13 eligible cohort studies had relevant 
data to examine the association between cognitive 
stimulation at work and dementia incidence (analysis 
1, see supplementary figure): the Finnish Public Sector 
study (FPS); GAZEL study, France; Health and Social 
Support (HeSSup) study, Helsinki Health Study (HHS), 
and Still Working study, Finland; the Whitehall II study, 
UK; and the Works, Lipids, and Fibrinogen (WOLF) 
Stockholm and Norrland studies, Sweden (fig 1). These 
studies comprised 107 896 men and women who were 
free of dementia at baseline (1986 to 2002), when 
cognitive stimulation and covariates were assessed. 
Follow-up for dementia was through to end of 2017.
To explore biological plausibility in a data driven 
analysis (analysis 2, see supplementary figure), we 
assessed 4953 proteins in plasma from a random 
sample of 2261 participants in one of the IPD-Work 
cohorts (the Whitehall II study)15 and examined 
associations between cognitive stimulation and 
plasma proteins (fig 1). Cognitive stimulation at 
work was assessed in 1991-93, and blood samples 
for the assessment of plasma protein were taken in 
1997-99. The participants were free of dementia at 
the assessment of cognitive stimulation and plasma 
proteins.
In analysis 3 (see supplementary figure), we examined 
associations between proteins and dementia. As a 
complementary dataset to Whitehall II with follow-up 
for dementia until October 2019, we included a non-
IPD-Work cohort, the multiethnic Atherosclerosis Risk 
in Communities (ARIC) study with 11 395 participants 
(fig 1).18 In ARIC, blood samples for protein analyses 
were drawn in 1993-95 and dementia follow-up was 
through to end of 2017. Cognitive stimulation at work 
was not measured in ARIC.
Table 1 summarises the study designs, participant 
numbers, and outcome ascertainment methods. 
Supplementary etables 1-8 show the characteristics of 
the cohorts.
Measurement of cognitive stimulation at work
We used predefined protocols to assess indicators 
of cognitive stimulation at work: job demands and 
job control. A description of the self-administered 
multi-item measures of these characteristics in each 
participating IPD-Work study and data harmonisation 
are available elsewhere and in the supplementary file 
(pp 13-14).19 Briefly, to minimise investigator bias, 
we validated and harmonised the job demand and 
control measures across participating cohort studies 
before extracting data for dementia, with investigators 
masked to outcome information. Questions in the 
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job demands and job control scales had Likert-type 
response formats. We computed mean response 
scores for job demand items and for job control items 
for each participant. High job demand was defined 
as having a job demand score that was greater than 
the study specific median score; we defined high job 
control as having a job control score that was higher 
than or equal to the study specific median score. These 
categorisations are the originals and most used. We 
used the dichotomised measures to construct three 
categories of cognitive stimulation at work along the 
active-passive work dimension of Karasek’s demand-
control model10 11 in which both high demands and 
high control indicate higher stimulation. We defined 
low cognitive stimulation at work as low demands 
and low control, medium cognitive stimulation as 
high control and low demands or high demands and 
low control, and high cognitive stimulation as high 
demands and high control. The supplementary file (pp 
13-14, efigure 1) provides a detailed description of the 
demand-control model.
To obtain an alternative continuous longitudinal 
measure unaffected by individual response style for 
supplementary analyses, we used a job exposure 
matrix indicator of cognitive stimulation that 
captures any changes of job and changes in level of 
stimulation over time. This measure was available 
for participants in the largest cohort study, the 
FPS. Data on participants’ occupational titles were 
obtained from Statistics Finland at baseline in 2000 
and at follow-up in 2005, 2010, and 2015 and were 
categorised according to the International Standard 
Classification of Occupations (ISCO-88) by the 
International Labour Organisation (www.ilo.org/
public/english/bureau/stat/isco/isco88/index.htm, 
accessed 3 July 2021). Using the three digit ISCO 
codes, we identified a total of 87 different occupations 
with at least 20 participants to determine the job axis 
for the job exposure matrix. The exposure axis was 
constructed by calculating the proportion of workers 
with high cognitive stimulation at work based on 
all responses within the same occupation. This 
occupation based exposure value was then assigned 
to each participant in the occupation (ranging from 
0% for booking clerks to 62% for city mayors and 
other top administrators) in 2000, 2005, 2010, and 
2015 or until the participant retired or was censored 
owing to dementia or death.
Included new IPD-Work study
7 studies included
12 original IPD-Work studies
Participants excluded
6 studies missing data on proteins
6544
Analysis 1: Analytic sample
6 studies excluded
3 missing outcome data


















Analysis 3: Analytic sample
11 395
13 656
Fig 1 | Selection of cohort studies to analyse three associations: cognitive stimulation-dementia (analysis 1), cognitive 
stimulation-proteins (analysis 2), and proteins-dementia (analysis 3). IPD-Work=individual participant data meta-
analysis in working populations; ARIC=Atherosclerosis Risk in Communities
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Covariates
Covariates were established dementia risk factors 
across the life course, as defined by the 2020 
Lancet Commission on Dementia.1 These included 
participants’ age and sex, obtained from national or 
employers’ registers or self-reported. Education, a 
measure of cognitive stimulation in childhood, was 
self-reported (GAZEL, HHS, Still Working, Whitehall, 
WOLF, HeSSup, ARIC), or obtained from national 
registers (FPS).20 Education was categorised into low 
(primary or lower secondary), intermediate (higher 
secondary), and high (tertiary qualification, college, or 
university) levels.
Risk factors in adulthood included smoking (current 
versus former or never smoker), alcohol consumption 
(heavy (>14 units/week in women, >21 units/week 
in men versus other; one unit is approximately 
equivalent to 10 g of ethanol), physical activity (high 
versus low), obesity (body mass index ≥30 versus 
<30), hypertension (yes versus no), and prevalent 
diabetes (yes versus no).21-26 Job strain (yes versus no) 
was measured with questions from the validated job 
content or demand-control questionnaire,19 and, as in 
other IPD-Work studies, was defined as high demands 
and low control, with all other combinations denoting 
no job strain.14 27
Because people with cardiometabolic disease have 
increased risk of dementia, covariates also included 
diabetes (diagnostic codes E10 and E11 in the 
international classification of diseases, 10th revision; 
ICD-10), coronary heart disease (non-fatal myocardial 
infarction, ICD-10 codes I21–I22, or coronary death 
recorded as ICD-10 I20–I25), and stroke (ICD-10 
codes I60, I61, I63, I64), including both prevalent 
cases at baseline and incident cases between baseline 
and before dementia diagnosis, assessed using linked 
records.
When possible we used additional covariates, 
available for specific cohorts only. Analyses of a 
longitudinal job exposure matrix indicator of cognitive 
stimulation (analysis 1) were based on the FPS study, 
with data on several additional dementia risk factors: 
social isolation (yes or no), depression (ICD-10 F32, 
F33), traumatic brain injury (ICD-10 S06), and atrial 
fibrillation (ICD-10 I48); the last three were identified 
from records of hospital admissions before dementia 
diagnosis. In protein analyses (analyses 2 and 3), we 
additionally adjusted effect estimates for ethnicity 
(white versus non-white) because more than 20% 
of the ARIC participants were non-white. In protein 
analyses based on the Whitehall II subcohort, APOE 
genotype (0, 1, or 2 of ε4 risk alleles), a strong predictor 
of dementia, was an additional covariate. Further in
ormation about additional covariates is available in 
the supplementary file (pp 14-15, etables 9-11).
Measurement of plasma proteins
Proteins were analysed using the SomaScan version 
4 assay (Somalogic, CO).15 The analyses used plasma 
EDTA samples collected in 1997-99 (Whitehall II) or 
1993-95 (ARIC) and stored at−80°C. Earlier studies 
and the supplementary file (p 16) describe in detail 
the performance of the SomaScan assay and the 
modified aptamer binding.28-30 Briefly, the assay 
uses a mix of thousands of slow off-rate modified 
aptamers (SOMAmers). The aptamers bind to proteins 
in participants’ plasma samples and the specificity 
is ensured by a two step process analogous to a 
Table 1 | Study populations in analyses on associations between cognitive stimulation, plasma proteins, and dementia
Analysis and cohorts Baseline Total No
Mean (SD) 








Cognitive stimulation-dementia (analysis 1)
GAZEL 1997 11 362 13.7 (1.4) 14 Self-reports, deaths –
WOLF 1992-95 10 368 14.1 (2.3) 25 Hospital admissions, deaths –
HeSSup 1998 15 534 14.8 (1.3) 50 Hospital admissions, prescriptions, deaths –
HHS 2000-02 6544 14.4 (1.8) 43 Hospital admissions, prescriptions, deaths –
Whitehall II 1991-93 7475 22.1 (3.4) 183 Hospital admissions, deaths –
FPS 2000-02 47 448 15.5 (1.6) 313 Hospital admissions, prescriptions, deaths –
Still Working 1986 9165 30.1 (2.2) 515 Hospital admissions, prescriptions, deaths –
Pooled total 107 896 16.7 (4.9) 1143
Cognitive stimulation-proteins (analysis 2)
Whitehall II (random sample):
 Cognitive stimulation 1991-93 2261 –
 Proteins 1997-99 2261 20.4 (3.2) 109 – Somascan, version 4
Proteins-dementia (analysis 3)
Whitehall II (random sample) 1997-99 2261 20.4 (3.2) 109 Hospital admissions, deaths Somascan, version 4
ARIC 1993-95 11 395 17.7 (6.1) 1942 Clinical examination, hospital admissions, deaths
Somascan, 
version 4
Total 13 656 18.1 2051
WOLF=Works, Lipids, and Fibrinogen Stockholm and Norrland studies; HeSSup=Health and Social Support study; FPS=Finnish Public Sector study; 
ARIC=Atherosclerosis Risk in Communities study.
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conventional immunoassay. The specificity of the 
aptamer reagents is good and has been tested in several 
ways.15 Median intra-assay and inter-assay coefficients 
of variation for SomaScan version 4 are about 5%, 
and assay sensitivity is comparable to that of typical 
immunoassays, with a median lower limit of detection 
in the femtomolar range.28
Follow-up for dementia
For the seven IPD-Work studies, including Whitehall 
II and its subcohort, we extracted data on dementia 
status at follow-up from hospital admissions records 
and death registries with any mention of dementia 
in the diagnosis, with or without reimbursements 
for medical treatment for dementia (Anatomical 
Therapeutic Chemical code N06D; table 1).20 
Electronic records included exact date of diagnosis, 
death, or entitlement to reimbursement, and follow-
up duration was measured as the difference between 
date of baseline examination and date of diagnosis, 
death, or entitlement to reimbursement. Although 
ascertainment of dementia from electronic health 
records underestimates prevalence, it has been shown 
to be a valid method in the study of associations 
between risk factors and dementia.31-33 ICD-10 codes 
for all cause dementia were F00, F01, F02, F03, G30, 
and G31, with earlier ICD codes converted to ICD-10 
codes (supplementary file p16). Codes F00 and G30 
were used to define Alzheimer’s disease.
In the ARIC study, adjudicated people with dementia 
were primarily identified using data from ARIC clinic 
examinations conducted at visits 5 (2011-13) and 6 
(2016-17). This included a neuropsychological battery 
using standardised protocols, with scores converted 
to z scores to assess change over time. Dementia was 
identified based on important decline on a serial 
cognitive battery, poor current test performance on 
a comprehensive neuropsychological battery, and 
impairments in activities of daily living based on 
informant rating on the clinical dementia rating 
scale and the functional activities questionnaire. A 
committee of clinicians then adjudicated participants 
with suspected dementia based on available cognitive 
and functional data. For participants who could not 
attend visits 5 or 6, those with dementia were identified 
through telephone cognitive assessment, plus 
surveillance of hospital discharge and death certificate 
codes related to dementia as well as screening during 
annual and semi-annual follow-up calls. Dementia 
suspected in participants who had died was identified 
through informant interviews.
Statistical analysis
We analysed the data in three parts (table 1). 
Cognitive stimulation at work was treated as a three 
level categorical variable, with low stimulation as 
the reference. The longitudinal job exposure matrix 
indicator of cognitive stimulation was analysed as a 
continuous exposure variable. In all three analyses, in 
multivariable models we adjusted effect estimates for 
age, sex, established dementia risk factors in childhood 
(education) and adulthood (smoking, heavy alcohol 
consumption, physical inactivity, job strain, obesity, 
hypertension, prevalent diabetes), and cardiometabolic 
diseases before dementia (ie, prevalent and incident 
diabetes, coronary heart disease, and stroke, treated 
as time dependent covariates). Before analysis, we 
imputed missing values in covariates using multiple 
imputation by substantive model compatible fully 
conditional specification.34 With data from all study 
variables, cohort indicator, and baseline year, 30 
imputed datasets were created for the pooled dataset, 
Whitehall II random sample, and ARIC cohort.
Analysis 1 (cognitive stimulation-dementia)
To examine associations of cognitively stimulating 
work with dementia risk, we followed each participant 
from the date of cognitive stimulation assessment 
to the first record of dementia, death, or the end of 
follow-up. We used a two stage approach, including 
study specific analyses with Cox regression in the 
first stage and pooling the study specific estimates 
with random effects meta-analysis in the second. 
To estimate heterogeneity among the study specific 
estimates, we calculated I2 (higher values denoting 
greater heterogeneity).
To examine the robustness of the findings, we 
performed separate analyses for men and women, 
younger (<60 years at baseline) and older participants 
(≥60 years at baseline), and an alternative, repeatedly 
measured job exposure matrix indicator of cognitive 
stimulation at work, entered into the model as a 
time dependent exposure. We also performed the 
analysis separately for incident dementia during 
the first 10 years of follow-up (when assessment of 
cognitively stimulating work might become inaccurate 
in the preclinical or prodromal stage of dementia) 
and incident dementia from year 10 onwards in 
those without a dementia diagnosis at year 10. The 
assumption in analyses separating the assessment of 
cognitively stimulating work and dementia diagnosis 
by at least 10 years is that the cognitive stimulation-
dementia association is less likely to be biased owing to 
reverse causation. To examine whether the association 
between cognitive stimulation and dementia depended 
on the method of dementia ascertainment, we 
stratified analyses by ascertainment method with the 
following categories: primary and specialised medical 
care (ascertainment based on self-report, prescription 
records, hospital admission, and death records) versus 
specialised medical care only (hospital admissions and 
death records). We also examined the association of 
cognitive stimulation with early onset (diagnosis aged 
<65) and late onset (diagnosis aged ≥65) dementia, 
Alzheimer’s disease, and non-Alzheimer’s disease 
dementia.
To address potential survival bias, we conducted a 
Fine and Gray competing risk analysis, with dementia 
and death as outcomes.35 In addition to the standard 
set of covariates (ie, age, sex, education, risk factors 
in adulthood, and cardiometabolic disease before 
dementia), we included cohort indicator as a covariate 
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in multivariable adjusted analyses based on pooled 
data. Further covariates, available for analyses of the 
longitudinal job exposure matrix indicator of cognitive 
stimulation, included social isolation, depression, 
traumatic brain injury, and atrial fibrillation at 
baseline.
Analysis 2 (cognitive stimulation-proteins)
The distribution of many of the plasma proteins 
was skewed. We applied rank based inverse normal 
transformation to achieve normal distributions. 
Logistic regression was used to study the associations 
of proteins with high versus low cognitive stimulation 
and medium versus low cognitive stimulation and 
were expressed as odds ratios per 1 standard deviation 
higher level of protein. Tests of statistical significance 
were corrected for multiple comparison using the 
Bonferroni method for 4953 tests (P<1.0×10−5). 
In addition to adjustments for the standard set 
of covariates, we adjusted the effect estimates for 
ethnicity and APOE genotype.
Analysis 3 (proteins-dementia)
Cox proportional hazards models were used to study 
associations between proteins that survived Bonferroni 
correction in analysis 2 and dementia. In the two 
cohorts, hazard ratios were computed for 1 standard 
deviation higher protein level, adjusting for age, 
sex, ethnicity, and the standard set of covariates. We 
conducted a Fine and Gray competing risk analysis to 
address potential survival bias.35 Cohort specific effect 
estimates were pooled using fixed effect meta-analysis.
Post hoc analyses
To examine the effect of cognitive stimulation across 
the life course, we created a life course measure of 
cognitive stimulation by combining education and 
cognitive stimulation at work into a single variable, 
including the categories low education-low cognitive 
stimulation (reference), low education-high cognitive 
stimulation, high education-low cognitive stimulation, 
and high education-high cognitive stimulation. 
Here the low category included the low and medium 
categories of the original education and cognitive 
stimulation measures. We used Cox regression to 
assess the age, sex, and cohort adjusted association 
between cognitive stimulation across the life course 
and incident dementia.
We used SAS (version 9.4) to analyse associations in 
each cohort and in the pooled data in analysis 1, Stata 
(version 16.1) for multiple imputations, meta-analyses 
combining cohort specific estimates, and protein 
analyses. The supplementary file (pp 26-33) shows the 
statistical code.
Patient and public involvement
This is a secondary analysis of pre-existing datasets. No 
patients were involved in setting the present research 
question, setting the outcome measures, or developing 
plans for recruitment, design, or implementation of 
the study. No patients were asked to advise on the 
interpretation, but we have received feedback from a 
patient reviewer of The BMJ. The dissemination plan 
targets a wide audience, including members of the 
public, patients, health professionals, and experts 
in the specialty through various channels: written 
communication, events and conferences, networks, 
and social media.
Results
Overall, 2488 (2.3%) of 110 394 eligible participants 
who had missing data for cognitive stimulation or 
incident dementia and 10 (<0.1%) with a diagnosis of 
Alzheimer’s disease or other dementia before the study 
baseline were excluded from analyses. Of 107 896 
participants included in the cognitive stimulation-
dementia analysis (table 2), 45 080 (41.8%) were men 
and 62 816 (58.2%) were women, with a mean age of 
44.6 (SD 9.5) years, at baseline. Of the participants, 
29 243 (27.1%) had low cognitive stimulation at work, 
50 724 (47.0%) had medium stimulation, and 27 929 
(25.9%) had high stimulation.
Cognitive stimulation-dementia risk
Mean follow-up for dementia varied between 13.7 
and 30.1 years depending on the cohort and was 
16.7 (SD 4.9) years in the total sample. During 
1 801 863 person years at risk, 1143 participants had 
a diagnosis of dementia between the ages of 42 and 
93 years, mean 71.2 (SD 7.9) years (supplementary 
efigure 2). Cumulative hazards of dementia by age 
and level of cognitive stimulation at baseline showed 
a separation in dementia occurrence between high 
and low stimulation groups such that the cumulative 
incidence of dementia seen in participants who had 
high cognitive stimulation at work was observed at a 
younger age in those who had low stimulation at work 
(fig 2). For example, the cumulative incidence at age 
75 in the high stimulation group (3.1%) was already 
observed at age 74 in the low stimulation group, and 
the incidence at age 80 (8.8%) was already observed at 
age 78.3, respectively. No difference in dementia was 
observed between participants with medium and low 
cognitive stimulation.
Meta-analysis of the seven cohort studies confirmed 
the association between high cognitive stimulation 
and lower risk of dementia in later life (fig 3). Incidence 
of dementia per 10 000 person years was 7.3 in the 
low cognitive stimulation group and 4.8 in the high 
stimulation group, the corresponding age and sex 
adjusted hazard ratio being 0.77 (95% confidence 
interval 0.65 to 0.92). This finding showed no 
significant heterogeneity across the cohorts (I2=0%, 
P=0.99) and the pattern of results was similar in 
the five cohorts with more than 25 participants with 
dementia (supplementary efigure 3). The association 
between higher cognitive stimulation and lower 
dementia risk was slightly weaker than that between 
education and dementia (hazard ratio 0.66, 95% 
confidence interval 0.55 to 0.79, supplementary etable 
12), but the association was statistically significant 
and robust in analyses stratified by sex, age, and 
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method of dementia ascertainment, before and after 
exclusion of participants with early onset dementia 
to minimise reverse causation, and before and after 
adjustment for established dementia risk factors in 
childhood and adulthood and the competing risk of 
death. The association was not mediated by prevalent 
or incident cardiometabolic diseases, although these 
diseases were related to increased dementia risk (age 
and sex adjusted hazard ratio 1.45, 95% confidence 
interval 1.23 to 1.71 for diabetes, 1.36, 1.08 to 1.72 
for coronary heart disease, and 1.90, 1.51 to 2.38 for 
stroke). There was an indication that the cognitive 
stimulation-dementia association was attributable to 
Alzheimer’s diseases rather than to other dementias 
(P=0.06).
In the FPS study, the mean for the job exposure 
matrix indicator of cognitive stimulation was 22.7% 
(SD 12.7%, range 0-62%). Repeating the analyses 
with this longitudinal, repeated measure of cognitive 
stimulation replicated the main findings (age and sex 
adjusted hazard ratio per 1 SD higher stimulation 0.77, 
95% confidence interval 0.69 to 0.86) (supplementary 
etable 13). This association remained after adjustment 
for established dementia risk factors, competing risk 
of death, and additional covariates, such as social 
isolation, depression, traumatic brain injury, and atrial 
fibrillation.
Cognitive stimulation, plasma proteins, and 
dementia risk
In the Whitehall subcohort with protein assessments, 
data from 4953 plasma proteins were available for 
2261 participants (supplementary etable 10). None 
of the participants had dementia at the assessment 
of cognitive stimulation and proteins. After correction 
for multiple testing and adjustment for age, sex, and 
ethnicity, levels of the following six proteins were 
found to be significantly lower among participants 
with high compared with low cognitive stimulation: 
pulmonary surfactant associated protein D (SP-
D), slit homologue 2 protein (SLIT2), hexokinase 2 
(HXK2), carbohydrate sulfotransferase 12 (CHSTC), 
peptidyl-glycine α-amidating monooxygenase (AMD), 
and neutrophil cytosol factor 1 (NCF-1) (table 3 and 
supplementary efigure 4). No association between 
medium versus low cognitive stimulation at work 
and plasma proteins reached Bonferroni adjusted 
significance. The inverse associations between high 
cognitive stimulation and low levels of the six proteins 
were independent of established dementia risk 
factors, cardiometabolic diseases, and APOE genotype 
(supplementary etable 14).
Analysis of the association between the six plasma 
proteins and dementia was based on data from the 
Whitehall subcohort and the ARIC study. Mean follow-
up for dementia after the assessment of proteins was 
20.4 (SD 3.2) years in the Whitehall subcohort and 
17.7 (SD 6.1) in ARIC, giving rise to 106 and 1942 
people with dementia, respectively. In age, sex, and 
ethnicity adjusted analysis of combined data from the 
Whitehall subcohort and ARIC, higher levels of SLIT2, 
CHSTC, and AMD were associated with increased 
dementia risk, or, conversely, lower protein levels 
were associated with lower dementia risk (table 4). 
The effect estimates did not materially change after 
adjustments (supplementary etables 15 and 16). No 
consistent association with dementia was seen for 
HXK2, SP-D, or NFC-1.
Post hoc analysis of cognitive stimulation in 
childhood and adulthood
A dose-response association was observed between 
cognitive stimulation over the life course and dementia 
such that cognitive stimulation in both childhood 
(education) and adulthood (cognitive stimulation at 
work) were related to a reduced risk of dementia (fig 4). 




 Men 45 080 (41.8)
 Women 62 816 (58.2)
Mean (SD) age (years) 44.6 (9.5)
Age group (years):
 <60 105 065 (97.4)
 ≥60 2831 (2.6)
Cognitive stimulation at work:
 Low 29 243 (27.1)
 Medium 50 724 (47.0)
 High 27 929 (25.9)
Education:
 Low 26 036 (25.1)
 Intermediate 40 723 (39.2)
 High 37 171 (35.8)
Current smoking:
 No 81 821 (79.1)
 Yes 21 580 (20.9)
Heavy alcohol intake:
 No 95 043 (89.7)
 Yes 10 950 (10.3)
Physical inactivity:
 No 82 030 (77.8)
 Yes 23 358 (22.2)
Obesity (BMI ≥30):
 No 86 611 (89.2)
 Yes 10 507 (10.8)
Hypertension:
 No 91 858 (86.9)
 Yes 13 878 (13.1)
Prevalent diabetes:
 No 105 199 (97.5)
 Yes 2680 (2.5)
Job strain:
 No 90 766 (84.1)
 Yes 17 130 (15.9)
Prevalent or incident diabetes:
 No 99 970 (92.8)
 Yes 7909 (7.3)
Prevalent or incident coronary heart disease:
 No 105 540 (97.8)
 Yes 2356 (2.2)
Prevalent or incident stroke:
 No 105 523 (97.8)
 Yes 2373 (2.2)
Supplementary eTables 1-7 present the characteristics of participants 
by cohort.
BMI=body mass index.
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The hazard ratio for high education and high cognitive 
stimulation at work compared with low education 
and low cognitive stimulation at work was 0.63 (95% 
confidence interval 0.49 to 0.82), whereas those 
for categories with high education or high cognitive 
stimulation at work, but not both, were 0.80 (0.66 to 
0.97) and 0.73 (0.61 to 0.89), respectively.
Discussion
In analysis of individual level data from more than 
100 000 people, those who worked in cognitively 
stimulating jobs showed a lower risk of dementia 
than those working in non-stimulating jobs. This 
finding was robust to adjustments for a range of 
established dementia risk factors in childhood 
and adulthood, cardiometabolic diseases, and the 
competing risk of death. The association did not 
differ between men and women or those younger and 
older than 60 and did not depend on the measure 
of cognitive stimulation at work or the method of 
dementia ascertainment, but there was an indication 
that the cognitive stimulation-dementia association 
was stronger for Alzheimer’s disease than for other 
dementias. Lower dementia incidence was observed 
even when 10 years or more separated the assessment 
of cognitive stimulation and the dementia diagnosis, 
suggesting that the findings were unlikely to be biased 
due to reverse causation. In data driven proteome-
wide analyses we identified three plasma proteins 
linked to both cognitive stimulation in adulthood and 
dementia, providing clues to underlying biological 
mechanisms.
Comparison with other studies
Cognitive decline characterises midlife and old age36 
and it has been suggested that cognitive stimulation 
might be one measure to slow this neurodegenerative 
process.1 Trial evidence on this possibility is, however, 
inconsistent. Long term cohort studies on leisure time 
cognitive activity have reported null findings, and 
observational studies on work complexity, intellectual 
engagement, and active jobs have been based on small 
samples, post hoc exposure measures, and insufficient 
control for confounding factors.2 3 7-9 37-39 Thus, both 
the World Health Organization dementia review40 and 
the 2020 Lancet Commission on Dementia Prevention, 
Intervention, and Care1 rated the evidence on the 
association between cognitive stimulation in adulthood 
and dementia as inconclusive and the quality of studies 
as very low to low. The 2020 Lancet Commission did 
not include cognitive stimulation in adulthood in the 
list of targets for dementia prevention.1
We hypothesised that methodological limitations 
and insufficient duration of cognitive stimulation in 
trial data might have resulted in these inconclusive 
findings. With the largest multicohort sample to date, 
rigorous confounder adjustments, and assessment 
of a cognitive stimulation exposure that is more long 
lasting than the cognitive interventions or cognitively 
stimulating hobbies examined in most previous 
studies, we obtained what we consider to be strong 
observational evidence for an association between 
cognitive stimulation in adulthood and dementia. 
This association was confirmed in a post hoc analysis 
that combined education and work related cognitive 
stimulation into a single variable. We found that higher 
cognitive stimulation in both childhood, as indicated 
by higher educational attainment, and adulthood, 
based on work characteristics, were associated with 
lower dementia risk in a stepwise dose-response 
manner. Together with mendelian randomisation 
analyses showing delayed dementia onset in those with 
higher education,41 these findings support the benefits 
of cognitive stimulation across the life course (see 
supplementary efigure 5 for a schematic presentation 
of this hypothesis).
Meaning of the study
The relative risk for low compared with high 
cognitive stimulation was 1.3, which is comparable 
to established dementia risk factors, such as high 
versus moderate alcohol consumption (relative risk 
1.2) and low versus high physical activity (1.4) but 
is smaller than those for education (1.6), diabetes 
(1.5), smoking (1.6), hypertension (1.6), and obesity 
(1.6).1 Our observational evidence on cognitive 
stimulation in adulthood is consistent with the “use 
it or lose it” principle. However, the robustness of the 
observed association to adjustment for a wide range 
of dementia risk factors, cardiometabolic diseases, 
and the competing risk of death raises the question of 
underlying mechanisms: if known risk factors do not 
drive the association, what then are the mediators?
We performed an exploratory and data driven 
plasma proteome analysis of biological mechanisms 
underlying the association between cognitive 
stimulation at work and risk of dementia. We identified 
three proteins, SLIT2, AMD, and CHSTC for which 
plasma levels were found to be significantly lower 
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Fig 2 | Crude cumulative hazard of dementia by age and level of cognitive stimulation at 
work
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  <60 years
  ≥60 years
Follow-up period
  First 10 years
  From year 10 onwards*
Dementia ascertainment
  Primary and specialised medical care
  Specialised medical care
Onset of dementia
  Early onset
  Late onset
Type of dementia
  Alzheimer's disease
  Other dementia
Adjustments
  Education†
  Adulthood risk factors‡
  Cardiometabolic diseases§
  All above¶
  Competing risk of death
1.00
0.99 (0.86 to 1.13)
0.77 (0.65 to 0.92)
1.00
0.91 (0.75 to 1.10)
0.75 (0.60 to 0.94)
1.00
1.07 (0.88 to 1.30)
0.77 (0.58 to 1.01)
1.00
0.99 (0.86 to 1.15)
0.76 (0.63 to 0.91)
1.00
0.92 (0.61 to 1.40)
0.80 (0.47 to 1.37)
1.00
0.89 (0.63 to 1.26)
0.60 (0.37 to 0.95)
1.00
1.00 (0.86 to 1.15)
0.79 (0.66 to 0.95)
1.00
0.98 (0.85 to 1.14)
0.76 (0.62 to 0.92)
1.00
1.02 (0.74 to 1.42)
0.83 (0.57 to 1.21)
1.00
0.85 (0.63 to 1.14)
0.71 (0.49 to 1.02)
1.00
1.03 (0.89 to 1.20)
0.79 (0.65 to 0.96)
1.00
0.91 (0.77 to 1.08)
0.72 (0.57 to 0.90)
1.00
1.29 (0.96 to 1.75)
1.09 (0.75 to 1.57)
1.00
1.03 (0.90 to 1.18)
0.82 (0.69 to 0.98)
1.00
0.86 (0.74 to 1.00)
0.77 (0.65 to 0.91)
1.00
0.97 (0.85 to 1.11)
0.77 (0.65 to 0.91)
1.00
0.89 (0.77 to 1.05)
0.82 (0.68 to 0.98)
1.00
0.98 (0.86 to 1.12)
0.79 (0.66 to 0.94)
0.25 0.5 21





















































































































































































































































Fig 3 | Association of cognitive stimulation at work with incident dementia in total sample, subgroups, by study follow-up and dementia type, and in 
relation to adjustments (analysis 1). *Follow-up started 10 years after baseline and the analysis included only those participants without a diagnosis 
of dementia by that time. †Adjusted for age, sex, cohort, and education. ‡Adjusted for age, sex, cohort, and smoking, alcohol consumption, physical 
inactivity, job strain, obesity, hypertension, and prevalent diabetes at baseline. §Adjusted for age, sex, and cohort, and diabetes, coronary heart 
disease, and stroke (prevalent at baseline and incident between baseline and dementia diagnosis). ¶Adjusted for age, sex, education, risk factors in 
adulthood, and cardiometabolic diseases
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among participants with cognitive stimulation at 
work, whereas high levels of these proteins were found 
to be associated with increased dementia incidence. 
Experimental findings from stem cells, tissue cultures, 
and animal models suggest that SLIT2 and AMD are 
involved in central nervous system related mechanisms 
that inhibit neuron projection axonogenesis, affect 
axon guidance, and increase nerve degeneration.42-45 
CHSTC has been linked to processes that inhibit 
axonogenesis and cause collapse of axonal growth 
cones and loss of synaptic connection.46-48 In light of 
this molecular evidence and given that dysregulated 
axonogenesis and synaptic disorganisation are the 
hallmarks of Alzheimer’s disease,49 our observations 
on plasma proteins are consistent with the hypothesis 
that protection against neurodegeneration might 
mediate the favourable effects of cognitive stimulation 
in adulthood. Further research is needed to confirm or 
refute this hypothesis.
Strengths and limitations of this study
The main strengths of the study are its large sample 
size, which reduces the risk of type 1 error, the 
availability of nearly 5000 plasma proteins to explore 
potential underlying mechanisms, and the use of 
multicohort analyses to provide a certain degree of 
validation for the main findings. Our study was based 
on preplanned exposure definitions and subgroup 
analyses, reducing the risk of reporting bias. We were 
also able to reduce the risk of reverse causation bias 
by excluding all participants with dementia during 
the first 10 years of follow-up. In main or sensitivity 
analyses, we adjusted effect estimates for 10 of the 
12 risk factors established for dementia by the 2020 
Lancet Commission (ie, education, smoking, heavy 
alcohol consumption, physical inactivity, obesity, 
hypertension, diabetes, social isolation, depression, 
and traumatic brain injury).1 The remaining two risk 
factors are hearing loss and air pollution. Hearing loss 
is, however, assumed to result in cognitive decline 
through reduced cognitive stimulation.1 Thus, hearing 
loss represents an alternative measure of cognitive 
stimulation rather than a confounding factor. We had 
no data on air pollution.
This study has several weaknesses. Because 
we used non-randomised observational data, we 
cannot draw conclusions about causality and cannot 
exclude residual confounding (eg, by childhood IQ) 
as an alternative explanation for our findings. As 
we focused on working age populations at baseline, 
follow-up was right truncated with a relatively low 
mean age at dementia diagnosis (mean 71, range 43-
93). This precluded assessment of lifelong effects in 
relation to cognitive stimulation. Rather than having 
a single dataset with complete information, we used 
a sequential approach in which we established the 
presence of the associations in separate analyses and 
separate cohorts: cognitive stimulation-dementia, 
cognitive stimulation-proteins, and proteins-dementia. 
The reason for this piecewise design was that complete 
data for all these variables were available only for 
a subgroup in one of the studies, Whitehall II. The 
sample size of this subgroup was insufficient for a 
formal mediation analysis of the role of proteins in 
the association between cognitive stimulation and 
dementia risk. Main analyses were based on a single 
self-reported measurement of cognitive stimulation at 
work. However, consistent results with an alternative, 
longitudinal job exposure matrix indicator of cognitive 
Table 3 | Proteins associated with cognitive stimulation in 2261 participants with plasma proteins available in Whitehall 
subcohort after controlling for multiple testing (analysis 2)
Protein
High v low cognitive stimulation Medium v low cognitive stimulation
β (SE)* P value β (SE)* P value
Pulmonary surfactant associated protein D (SP-D) −0.32 (0.06) <0.001 -0.17 (0.06) 0.002
Slit homologue 2 protein (SLIT2) −0.30 (0.06) <0.001 −0.17 (0.06) 0.002
Hexokinase 2 (HXK2) −0.28 (0.06) <0.001 −0.13 (0.06) 0.019
Carbohydrate sulfotransferase 12 (CHSTC) −0.28 (0.06) <0.001 −0.08 (0.06) 0.18
Peptidyl-glycine α-amidating monooxygenase (AMD) −0.28 (0.06) <0.001 −0.12 (0.06) 0.03
Neutrophil cytosol factor 1 (NCF-1) −0.27 (0.06) <0.001 −0.06 (0.06) 0.28
*Per 1 standard deviation higher protein level. Only statistically significant associations after adjustment for age, sex, ethnicity, and Bonferroni correction 
for multiple testing (P<1.0×10−5) are shown for high versus low cognitive stimulation.






Adjusted hazard ratio  




 Whitehall 2261 109 1.19 (0.97 to 1.45)
 ARIC 11 395 1942 1.12 (1.00 to 1.26) Yes
 Both 13 656 2051 1.14 (1.03 to 1.25)
CHSTC:
 Whitehall 2261 109 1.08 (0.90 to 1.31)
 ARIC 11 395 1942 1.22 (1.05 to 1.41) Yes
 Both 13 656 2051 1.17 (1.04 to 1.31)
AMD:
 Whitehall 2261 109 1.11 (0.92 to 1.34)
 ARIC 11 395 1942 1.07 (0.99 to 1.16) Yes
 Both 13 656 2051 1.08 (1.00 to 1.16)
HXK2:
 Whitehall 2261 109 1.09 (0.91 to 1.31)
 ARIC 11 395 1943 1.03 (0.92 to 1.15) No
 Both 13 656 2051 1.05 (0.95 to 1.15)
SP-D:
 Whitehall 2261 109 1.16 (0.95 to 1.40)
 ARIC 11 395 1943 0.98 (0.93 to 1.04) No
 Both 13 656 2051 0.99 (0.94 to 1.05)
NCF-1:
 Whitehall 2261 109 0.94 (0.78 to 1.13)
 ARIC 11 395 1943 1.25 (1.12 to 1.41) No
 Both 13 656 1944 1.16 (1.05 to 1.28)
AMD=peptidyl-glycine α-amidating monooxygenase; ARIC=Atherosclerosis Risk in Communities; 
CHSTC=carbohydrate sulphotransferase 12; HXK2=hexokinase 2; NCF-1=neutrophil cytosol factor 1; SLIT2=slit 
homologue 2 protein; SP-D=pulmonary surfactant associated protein D.
*Adjusted for age, sex, and ethnicity.
†Hazard ratio >1 in both cohort studies and P<0.05 in pooled analysis.
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stimulation suggest this is an unlikely source of 
major bias in this study. Except for one cohort in 
which dementia was diagnosed in repeated clinical 
examinations (ARIC), ascertainment of dementia was 
based on linkage to electronic health records, mostly 
hospital admissions. Although this had the advantage 
of providing data for everyone recruited to the study, it 
misses participants with milder dementia and is not the 
gold standard method for assessing dementia subtypes.
Generalisability, implications, and future 
challenges
These results seem to be generalisable across different 
populations. Although we used cohort studies 
from different settings (civil servants, public sector 
employees, forestry workers), little heterogeneity 
existed in the cohort specific estimates of dementia 
(heterogeneity I2=0%). In addition, the association 
between cognitive stimulation at work and lower 
dementia risk was observed across subgroups; men 
and women and those younger and older than 60 at 
baseline. These robust findings might be important 
for policy, suggesting that cognitively stimulating 
work for all will be important for future brain health. 
However, further research capturing the full range of 
occupations and countries outside Europe is needed to 
confirm the generalisability of our findings.
Our findings on proteins were consistent across the 
two cohorts with relevant data but owing to smaller 
numbers and less precise estimates these results 
need further validation in other studies. If confirmed, 
the associations might provide clues to search for 
mechanisms underlying long term risk of dementia 
in humans. As the proteins identified in this study are 
associated with a wide range of biological processes 
beyond neural influences, their effects should be 
comprehensively examined.
Conclusions
This multicohort study of more than 100 000 
participants suggests that people with cognitively 
stimulating jobs have a lower risk of dementia in old 
age than those with non-stimulating jobs. A possible 
mechanism for this association is the finding that 
cognitive stimulation is associated with lower levels of 
plasma proteins that might inhibit axonogenesis and 
synaptogenesis and increase dementia risk in old age.
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Fig 4 | Association of cognitive stimulation over the life course with incident dementia (post hoc analysis)
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